Charles Schwab Investment Management Inc. Purchases 23,601 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Charles Schwab Investment Management Inc. grew its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 4.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 508,398 shares of the company’s stock after buying an additional 23,601 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Replimune Group were worth $6,157,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its holdings in Replimune Group by 24.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock worth $198,000 after acquiring an additional 3,177 shares during the period. SG Americas Securities LLC raised its stake in shares of Replimune Group by 14.7% during the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock worth $318,000 after purchasing an additional 3,374 shares during the period. MetLife Investment Management LLC boosted its holdings in shares of Replimune Group by 21.5% in the 3rd quarter. MetLife Investment Management LLC now owns 35,134 shares of the company’s stock worth $385,000 after buying an additional 6,216 shares during the last quarter. BNP Paribas Financial Markets grew its position in Replimune Group by 81.7% during the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock valued at $165,000 after buying an additional 6,748 shares during the period. Finally, Rhumbline Advisers increased its holdings in Replimune Group by 8.3% during the fourth quarter. Rhumbline Advisers now owns 95,465 shares of the company’s stock worth $1,156,000 after buying an additional 7,317 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Trading Up 2.1 %

NASDAQ:REPL opened at $11.05 on Tuesday. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00. The stock’s fifty day moving average price is $12.66 and its two-hundred day moving average price is $12.16. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The company has a market cap of $851.02 million, a P/E ratio of -3.60 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). As a group, analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current year.

Wall Street Analyst Weigh In

REPL has been the topic of a number of research analyst reports. HC Wainwright boosted their target price on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Jefferies Financial Group upped their price objective on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. JPMorgan Chase & Co. raised their target price on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, BMO Capital Markets upped their price target on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Replimune Group presently has an average rating of “Buy” and a consensus target price of $19.43.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.